Lysophospholipids: A Potential Drug Candidates for Neurodegenerative Disorders
Neurodegenerative diseases (NDs) commonly present misfolded and aggregated proteins. Considerable research has been performed to unearth the molecular processes underpinning this pathological aggregation and develop therapeutic strategies targeting NDs. Fibrillary deposits of α-synuclein (α-Syn), a...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/12/3126 |
| _version_ | 1797461285137285120 |
|---|---|
| author | Tatsuya Karaki Hisao Haniu Yoshikazu Matsuda Tamotsu Tsukahara |
| author_facet | Tatsuya Karaki Hisao Haniu Yoshikazu Matsuda Tamotsu Tsukahara |
| author_sort | Tatsuya Karaki |
| collection | DOAJ |
| description | Neurodegenerative diseases (NDs) commonly present misfolded and aggregated proteins. Considerable research has been performed to unearth the molecular processes underpinning this pathological aggregation and develop therapeutic strategies targeting NDs. Fibrillary deposits of α-synuclein (α-Syn), a highly conserved and thermostable protein, are a critical feature in the development of NDs such as Alzheimer’s disease (AD), Lewy body disease (LBD), Parkinson’s disease (PD), and multiple system atrophy (MSA). Inhibition of α-Syn aggregation can thus serve as a potential approach for therapeutic intervention. Recently, the degradation of target proteins by small molecules has emerged as a new therapeutic modality, gaining the hotspot in pharmaceutical research. Additionally, interest is growing in the use of food-derived bioactive compounds as intervention agents against NDs via functional foods and dietary supplements. According to reports, dietary bioactive phospholipids may have cognition-enhancing and neuroprotective effects, owing to their abilities to influence cognition and mental health in vivo and in vitro. However, the mechanisms by which lipids may prevent the pathological aggregation of α-Syn warrant further clarification. Here, we review evidence for the potential mechanisms underlying this effect, with a particular focus on how porcine liver decomposition product (PLDP)-derived lysophospholipids (LPLs) may inhibit α-Syn aggregation. |
| first_indexed | 2024-03-09T17:18:00Z |
| format | Article |
| id | doaj.art-328e4b078c504538b4bb25e89ff77aa0 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T17:18:00Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-328e4b078c504538b4bb25e89ff77aa02023-11-24T13:27:16ZengMDPI AGBiomedicines2227-90592022-12-011012312610.3390/biomedicines10123126Lysophospholipids: A Potential Drug Candidates for Neurodegenerative DisordersTatsuya Karaki0Hisao Haniu1Yoshikazu Matsuda2Tamotsu Tsukahara3Department of Pharmacology and Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, JapanInstitute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, 3-1-1 Asahi, Nagano 390-8621, JapanClinical Pharmacology Educational Center, Nihon Pharmaceutical University, Ina-machi, Saitama 362-0806, JapanDepartment of Pharmacology and Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, JapanNeurodegenerative diseases (NDs) commonly present misfolded and aggregated proteins. Considerable research has been performed to unearth the molecular processes underpinning this pathological aggregation and develop therapeutic strategies targeting NDs. Fibrillary deposits of α-synuclein (α-Syn), a highly conserved and thermostable protein, are a critical feature in the development of NDs such as Alzheimer’s disease (AD), Lewy body disease (LBD), Parkinson’s disease (PD), and multiple system atrophy (MSA). Inhibition of α-Syn aggregation can thus serve as a potential approach for therapeutic intervention. Recently, the degradation of target proteins by small molecules has emerged as a new therapeutic modality, gaining the hotspot in pharmaceutical research. Additionally, interest is growing in the use of food-derived bioactive compounds as intervention agents against NDs via functional foods and dietary supplements. According to reports, dietary bioactive phospholipids may have cognition-enhancing and neuroprotective effects, owing to their abilities to influence cognition and mental health in vivo and in vitro. However, the mechanisms by which lipids may prevent the pathological aggregation of α-Syn warrant further clarification. Here, we review evidence for the potential mechanisms underlying this effect, with a particular focus on how porcine liver decomposition product (PLDP)-derived lysophospholipids (LPLs) may inhibit α-Syn aggregation.https://www.mdpi.com/2227-9059/10/12/3126lysophospholipidsneurodegenerative diseasesamyloidα-synuclein |
| spellingShingle | Tatsuya Karaki Hisao Haniu Yoshikazu Matsuda Tamotsu Tsukahara Lysophospholipids: A Potential Drug Candidates for Neurodegenerative Disorders Biomedicines lysophospholipids neurodegenerative diseases amyloid α-synuclein |
| title | Lysophospholipids: A Potential Drug Candidates for Neurodegenerative Disorders |
| title_full | Lysophospholipids: A Potential Drug Candidates for Neurodegenerative Disorders |
| title_fullStr | Lysophospholipids: A Potential Drug Candidates for Neurodegenerative Disorders |
| title_full_unstemmed | Lysophospholipids: A Potential Drug Candidates for Neurodegenerative Disorders |
| title_short | Lysophospholipids: A Potential Drug Candidates for Neurodegenerative Disorders |
| title_sort | lysophospholipids a potential drug candidates for neurodegenerative disorders |
| topic | lysophospholipids neurodegenerative diseases amyloid α-synuclein |
| url | https://www.mdpi.com/2227-9059/10/12/3126 |
| work_keys_str_mv | AT tatsuyakaraki lysophospholipidsapotentialdrugcandidatesforneurodegenerativedisorders AT hisaohaniu lysophospholipidsapotentialdrugcandidatesforneurodegenerativedisorders AT yoshikazumatsuda lysophospholipidsapotentialdrugcandidatesforneurodegenerativedisorders AT tamotsutsukahara lysophospholipidsapotentialdrugcandidatesforneurodegenerativedisorders |